Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Down 65.8% in May

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totaling 49,381 shares, a decline of 65.8% from the April 30th total of 144,231 shares. Based on an average daily trading volume, of 338,840 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on FSNUY shares. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, April 20th. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Fresenius SE & Co. has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Performance

Shares of FSNUY stock traded down $0.14 during midday trading on Friday, hitting $10.64. 156,060 shares of the company were exchanged, compared to its average volume of 179,826. Fresenius SE & Co. has a 52 week low of $10.60 and a 52 week high of $33.93. The firm has a market capitalization of $23.97 billion, a P/E ratio of 14.19 and a beta of 0.68. The firm’s 50 day moving average price is $12.23 and its two-hundred day moving average price is $13.57. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.00 and a current ratio of 1.32.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.29% and a net margin of 6.55%.The company had revenue of $6.75 billion for the quarter, compared to analyst estimates of $6.79 billion. As a group, equities research analysts anticipate that Fresenius SE & Co. will post 1.05 earnings per share for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.